Abstract
Abstract
Herceptin is considered an essential treatment option for double negative breast cancer. Resveratrol and didox are known chemopreventive agents with potential anticancer properties. The aim of the current study is to investigate the influence of resveratrol and didox on the cytotoxicity profile of herceptin in her-2 receptor positive and her-2 receptor negative breast cancer cell lines. The IC50's of herceptin in T47D and MCF-7 were 0.126±0.01 ng/ml and 26.71±1.85 ng/ml respectively. Equitoxic combination of herceptin with resveratrol or didox in T47D significantly reduced the IC50 to 0.05±0.01 and 0.029±0.006 ng/ml, respectively and similar results were obtained in MCF-7. The gene expression of Bcl-xl was markedly decreased in T47D cells following treatment with herceptin/resveratrol compared to herceptin alone. Immunocytochemical staining of her-2 receptor in T47D cells showed a significant reduction after treatment with herceptin/resveratrol combination compared to herceptin alone. On the other hand, combination of herceptin and didox had no significant effect on her-2 receptor expression. Cell cycle analysis showed an arrest at G2/M phase for both cell lines following treatment with herceptin alone and in either combinations regimen. In conclusion the combination of herceptin with resveratrol and didox improved the cytotoxic profile of herceptin in T47D (her-2 receptor positive cell line) and to a lesser extent in MCF-7 (her-2 receptor negative cell line).
Citation Format: Ghada A. Abd Ellatif, Marianne Georges Tadros, Ashraf Bahey Eldin Abd El Naim, Amany Ibrahim Khalifa, Ahmad M. Alabd. The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5114. doi:10.1158/1538-7445.AM2014-5114